BIGBEAR
PHARMACEUTICALS
Crizotinib is an oral small-molecule multi-target tyrosine kinase inhibitor, and the world’s first approved targeted antineoplastic agent for both ALK and ROS1. Its common dosage form is capsules.
AuthenticGuaranteeFast DeliveryPrivacy IndicationsCrizotinib, also known as XALKORI, is indicated for the treatment of:ALK‑positive or ROS1‑positive metastatic non‑small cell lung cancer (N···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 69
Indications and Mechanism of ActionCrizotinib is indicated for patients with ALK‑positive locally advanced or metastatic non‑small cell lung cancer (N···【Read More】
Update: 09 Mar,2026Source: Haiou HealthViews: 70
Copyright2024@ BIGBEAR All right reserved BIGBEAR
